Interleukin-10 modulation of alloreactivity and graft-versus-host reactions.
- 1 September 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 74 (6) , 772-778
- https://doi.org/10.1097/00007890-200209270-00007
Abstract
The biological properties of interleukin (IL)-10 in tolerance induction and inhibition of alloreactivity have suggested a therapeutic use of this cytokine as an additional or alternative prophylaxis for graft-versus-host disease (GvHD). However, the effects of exogenous IL-10 on GvHD are mainly studied in animal models, and the results remain conflicting. This study aims to demonstrate, for the first time, whether the addition of exogenous IL-10 can reduce the severity of graft-versus-host reactions (GvHR) in humans. The regulatory role of exogenous IL-10 in GvHR was investigated using an in vitro human skin explant model. The effects of IL-10 on skin GvHR were tested in parallel with allo-antigen induced T-cell proliferation, cytolytic reactivity, and cytokine production. In the presence of IL-10, the mixed lymphocyte reaction (MLR) primed responder cells showed significantly lower proliferative and cytolytic responses compared with the responder cells from the control MLR carried out in the absence of IL-10. The responder cells from IL-10 containing MLR induced significantly less severe skin GvHR and displayed a significantly reduced T-cell activation and cytokine production. A significant correlation was observed between the levels of TNF-α production and the sensitivity to IL-10 modulation of GvHR. The addition of exogenous IL-10 strongly inhibited the broad alloreactivity initiated by primary MLR and significantly reduced the overall severity of skin GvHR induced by MLR primed responder cells. Responder cells producing high TNF-α following allogeneic stimulation appeared to be less sensitive to IL-10 modulation of GvHR.Keywords
This publication has 20 references indexed in Scilit:
- PREDICTING GRAFT-VERSUS-HOST DISEASE IN HLA-IDENTICAL BONE MARROW TRANSPLANTSTransplantation, 1998
- High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantationBone Marrow Transplantation, 1997
- NK1.1+ T cell receptor-alpha/beta+ cells: new clues to their origin, specificity, and function.The Journal of Experimental Medicine, 1995
- Immunosuppressive and Anti-inflammatory Properties of Interleukin 10Annals of Medicine, 1995
- Proliferating dendritic cell progenitors in human blood.The Journal of Experimental Medicine, 1994
- Interleukin‐10 inhibits B7 and intercellular adhesion molecule‐1 expression on human monocytesEuropean Journal of Immunology, 1994
- High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells.The Journal of Experimental Medicine, 1994
- Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.The Journal of Experimental Medicine, 1991
- T CELL SUBSETS AND GRAFT-VERSUS-HOST DISEASETransplantation, 1987
- An in Vitro Predictive Test for Graft versus Host Disease in Patients with Genotypic HLA-Identical Bone Marrow TransplantsNew England Journal of Medicine, 1985